Insider Selling: SI-Bone Inc (NASDAQ:SIBN) CFO Sells 2,518 Shares of Stock

SI-Bone Inc (NASDAQ:SIBN) CFO Laura Francis sold 2,518 shares of the stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $17.92, for a total value of $45,122.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Laura Francis also recently made the following trade(s):

  • On Thursday, July 18th, Laura Francis sold 485 shares of SI-Bone stock. The stock was sold at an average price of $20.00, for a total value of $9,700.00.
  • On Tuesday, May 28th, Laura Francis sold 6,486 shares of SI-Bone stock. The stock was sold at an average price of $15.97, for a total value of $103,581.42.
  • On Thursday, May 16th, Laura Francis sold 2,000 shares of SI-Bone stock. The stock was sold at an average price of $15.96, for a total value of $31,920.00.

Shares of SIBN traded down $0.45 during midday trading on Friday, hitting $19.73. 178,007 shares of the company’s stock traded hands, compared to its average volume of 218,367. SI-Bone Inc has a 1 year low of $14.08 and a 1 year high of $23.03. The company’s fifty day moving average is $18.45. The company has a quick ratio of 12.70, a current ratio of 13.06 and a debt-to-equity ratio of 0.47. The firm has a market cap of $484.65 million and a PE ratio of -27.79.

SI-Bone (NASDAQ:SIBN) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.13). The firm had revenue of $14.99 million during the quarter. As a group, research analysts expect that SI-Bone Inc will post -1.45 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SIBN. Orbimed Advisors LLC acquired a new position in shares of SI-Bone in the 4th quarter valued at $20,584,000. RTW Investments LP acquired a new position in shares of SI-Bone in the 4th quarter valued at $16,802,000. BlackRock Inc. acquired a new position in shares of SI-Bone in the 4th quarter valued at $15,835,000. Pura Vida Investments LLC acquired a new position in shares of SI-Bone in the 4th quarter valued at $4,485,000. Finally, Foresite Capital Management IV LLC acquired a new position in shares of SI-Bone in the 4th quarter valued at $4,295,000. 38.89% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have weighed in on the company. ValuEngine lowered Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research lowered Yatra Online from a “hold” rating to a “sell” rating in a report on Saturday, July 6th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $24.75.

SI-Bone Company Profile

SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Insider Buying and Selling by Quarter for SI-Bone (NASDAQ:SIBN)

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.